Biomedical subjects
Publications and source records attributed to P Peltola.
Ketoprofen is better tolerated than the other most common non-steroidal anti-inflammatory drugs. Cross-reactivity in the form of allergic reactions appears almost non-existent. The G.I. symptoms are less pronounced with ketoprofen than with the other drugs tested so far.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A double-blind cross-over trial was carried out in 50 patients with definite rheumatoid arthritis, in order to compare the effects of 300 mg/day of ketoprofen with those of 600 mg/day of phenylbutazone, e.g. the maximal clinically used doses of each drug. The treatment period on each drug was two weeks. There was no statistically significant difference between the drugs with the six parameters studied, either on subjective or objective evaluation. Both drugs were superior to the conventional treatment given before the trial. The side-effects did not differ significantly for each product, except that the central nervous symptoms were less frequent with ketoprofen. Ketoprofen thus seems to be an effective and acceptable drug for the treatment of patients with rheumatoid arthritis.
The tolerance of ketoprofen (2-(3-benzoylphenyl)-propionic acid) was studied in sixteen patients with rheumatoid arthritis during a treatment period up to seven months. The drug was well tolerated with only a few minor side-effects and showed a clear anti-rheumatie effect with a dose of 150 mg/day. This effect may equal that of 4.0 g/day of acetylsalicylic acid or even exceed that, and may be somewhat smaller than that of 600 mg/day of phenylbutazone.
Explore the source record for details and available documents.